BTK-IN-22

• Description :

  BTK-IN-22 is a BTK inhibitor (IC50: 0.9 nM) . BTK-IN-22 also inhibits BLX and BMX with IC50s of 1.4 and 1.2 nM respectively. BTK-IN-22 shows improved kinase selectivity compared to Ibrutinib (HY-10997) [1]

• CAS Number :

  [2573048-10-7]

• UNSPSC :

  12352005

• Target :

  Btk

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/btk-in-22.html

• Solubility :

  10 mM in DMSO

• Smiles :

  C=CC(N1CCC[C@@H](C1)N2N=C(C3=C(N=CN=C32)N)C4=CC=C(C=C4C)OC5=CC=CC=C5)=O

• Molecular Formula :

  C26H26N6O2

• Molecular Weight :

  454.52

• References & Citations :

  [1]Sean T. Toenjes, et al. Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. ACS Med. Chem. Lett. 2023. https://doi.org/10.1021/acsmedchemlett.2c00523

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported